DILTIAZEM HYDROCHLORIDE

Post-LOE

diltiazem hydrochloride

Gen Pharmaceuticals

ANDAORALTABLET

Approved

Sep 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DILTIAZEM HYDROCHLORIDE (diltiazem hydrochloride) by Gen Pharmaceuticals is mechanisms of action although precise mechanisms of its antianginal actions are still being delineated, diltiazem hydrochloride is believed to act in the following ways: angina due to coronary artery spasm: diltiazem hydrochloride has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Approved for chronic stable angina, angina due to coronary artery spasm. First approved in 2022.

Drug data last refreshed 22h ago

Mechanism of Action

Mechanisms of Action Although precise mechanisms of its antianginal actions are still being delineated, diltiazem hydrochloride is believed to act in the following ways: Angina Due to Coronary Artery Spasm: Diltiazem hydrochloride has been shown to be a potent dilator of coronary arteries both…

Worked on DILTIAZEM HYDROCHLORIDE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DILTIAZEM HYDROCHLORIDE

Mechanism of Action

Indications (2)